Zimberelimab Monotherapy Proves Safe, Effective in PD-L1–Positive Cervical CancerDecember 5th 2022
Zimberelimab demonstrated encouraging efficacy with a tolerable safety profile in patients with PD-L1–positive recurrent or metastatic cervical cancer who had progressed after first- or subsequent-line, platinum-containing chemotherapy.
Enzalutamide Inspires Meaningful Delay in PSA Progression For Patients With PSA-Recurrent High-Risk Prostate CancerDecember 3rd 2022
Combining enzalutamide with salvage radiation therapy helped delay prostate-specific antigen progression in patients with PSA-recurrent, high-risk prostate cancer.
Researchers at Sylvester, Frost School Receive $2.6M Federal Grant to Study Mindfulness and Music TherapyDecember 2nd 2022
Researchers with Sylvester Comprehensive Cancer Center, part of the University of Miami Miller School of Medicine, and the University’s Frost School of Music are using a $2.6 million federal grant to study how mindfulness and music therapy can alleviate stress, anxiety, and depression, reduce treatment-related symptoms, and improve quality of life for cancer patients and survivors.
Olutasidenib Approved for IDH1-Mutated Acute Myeloid LeukemiaDecember 2nd 2022
The FDA has approved olutasidenib capsules to treat patients with relapsed or refractory acute myeloid leukemia with identified an IDH1-mutation. The label comes with a boxed warning for differentiation syndrome, and a warning for hepatotoxicity.
Benefit-Risk Profile of Trastuzumab/Pertuzumab With FLOT Regimen Comes Into Question in HER2-positive Gastric CancerDecember 1st 2022
Trastuzumab and pertuzumab with a chemotherapy regimen of fluorouracil, leucovorin, oxaliplatin, and docetaxel increased response, and high-grade toxicity, in patients with HER2-positive gastric or gastroesophageal junction cancer.
Pembrolizumab Combination Delivers Overall Survival Benefit in HER2-Negative Gastric/GEJ AdenocarcinomaNovember 29th 2022
Pembrolizumab plus physician’s choice of chemotherapy bested placebo plus chemotherapy in improving overall survival rates in patients with HER2-negative gastric cancer or gastroesophageal junction adenocarcinoma, regardless of PD-L1 expression.
Fewer Cycles of Oxaliplatin Treatment May Reduce Incidence of Severe Neuropathy for Patients With Stage III Colon CancerNovember 29th 2022
An observational study of 2450 patients with stage III colon cancer identified key factors that may increase a patient’s risk of oxaliplatin-induced peripheral neuropathy.
Ponatinib Outperforms Imatinib in Newly Diagnosed Philadelphia Chromosome+ Acute Lymphoblastic LeukemiaNovember 27th 2022
Combining ponatinib with reduced-intensity chemotherapy elicited a high rate of minimal residual disease (MRD)-negative complete remissions and no new safety signals in patients with Philadelphia chromosome–positive acute lymphoblastic leukemia.
Geriatric Assessment Intervention Helps Reduce Symptom Burden for Older Patients With Advanced CancerNovember 23rd 2022
Providing oncologists with a baseline geriatric assessment summary with guidelines to manage toxicities may help reduce symptom burden in older patients with advanced cancer.
First-Line Tremelimumab/Durvalumab/Chemotherapy May Become New Standard of Care in EGFR/ALK Wild-Type NSCLCNovember 22nd 2022
The combination of tremelimumab plus durvalumab plus chemotherapy, which was recently approved for patients with non–small cell lung cancer, could represent a new standard of care.
Coadministration of CD19 and CD22-Directed CAR T-cell Therapy Elicits Durable Remissions in Pediatric Patients With B-ALLNovember 21st 2022
Coadministration CD19- and CD22-directed CAR T-cell therapy produced relatively durable remissions in children with high-risk hematologic or isolated extramedullary relapse of B-acute lymphoblastic leukemia.
Osimertinib Still Holds The Crown in EGFR-Mutated Non-Small Cell Lung CancerNovember 19th 2022
As of November 2022, osimertinib is the preferred choice for the frontline treatment of EGFR-mutated non-small cell lung cancer. However, some experts believe that combination chemotherapy plus EGFR TKI will become a standard frontline treatment.